Each filer's latest filing for 29337E102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
15.0% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 15.0% | |||
| Abigail P. Johnson | 15.0% | |||
|
Orbimed Advisors LLC
13D/A
|
9.5% |
6/24/2026
Event 6/22/2026
|
||
| Orbimed Advisors LLC | 9.5% | |||
| Orbimed Capital GP VII LLC | 9.2% | |||
| Orbimed Genesis GP LLC | 0.3% | |||
| Orbimed Capital LLC | 0% | |||
|
Polar Capital Holdings Plc
13G/A
|
8.5% |
6/22/2026
Event 3/31/2026
|
||
| Polar Capital Holdings Plc | 8.5% | |||
| Polar Capital LLP | 8.5% | |||
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | |||
|
Commodore Capital LP
13G/A
|
7.7% |
5/15/2026
Event 3/31/2026
|
||
| Commodore Capital LP | 7.7% | |||
| Commodore Capital Master LP | 7.7% | |||
| Robert Egen Atkinson | 7.7% | |||
| Michael Kramarz | 7.7% | |||
| BlackRock, Inc. 13G/A | 7.1% |
10/27/2026
Event 9/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Vestal Point Capital, LP
13G/A
|
4.4% |
11/16/2026
Event 9/30/2026
|
||
| Vestal Point Capital, LP | 4.4% | |||
| Ryan Wilder | 4.4% | |||
|
Fairmount Funds Management LLC
13G/A
|
3.1% |
5/15/2026
Event 3/31/2026
|
||
| Fairmount Funds Management LLC | 3.1% | |||
| Fairmount Healthcare Fund II L.P. | 3.1% | |||
| Peter Harwin | 3.1% | |||
| Kiselak Tomas | 3.1% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
2.8% |
5/15/2026
Event 3/31/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | |||
| VHCP Co-Investment Holdings III, LLC | 2.8% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 2.8% | |||
| VHCP Management III, LLC | 2.8% | |||
| VHCP Management EG, LLC | 2.8% | |||
| Nimish Shah | 2.8% | |||
| Bong Y. Koh | 2.8% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 220 | 82.6 M | $3.79B |
| 2026 Q2 | 215 | 80.2 M | $4.06B |
| 2026 Q1 | 174 | 62.8 M | $2.44B |
| 2025 Q4 | 128 | 62.4 M | $961M |
| 2025 Q3 | 135 | 59.4 M | $1.22B |
| 2025 Q2 | 127 | 59.4 M | $1.19B |
| 2025 Q1 | 124 | 49.9 M | $984M |
| 2024 Q4 | 116 | 49.6 M | $1.12B |
| 2024 Q3 | 104 | 47.7 M | $1.22B |
| 2024 Q2 | 96 | 48.3 M | $1.13B |
| 2024 Q1 | 75 | 44.5 M | $781M |
| 2023 Q4 | 63 | 39.0 M | $540M |
| 2023 Q3 | 63 | 39.1 M | $534M |
| 2023 Q2 | 64 | 39.1 M | $798M |
| 2023 Q1 | 45 | 33.6 M | $735M |